Compass veers off course, delaying phase 3 psychedelic data and laying off 30% of staff | Cannabis Law Report | Where to order Skittles Moonrock online
Learn where to buy CBD Vape online. TOP QUALITY GRADE A++
Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.
👉 Click here to Visit our shop! 🛒
Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With the trials overrunning by months, the biotech is laying off 30% of its employees—including some senior managers—and focusing all its efforts on its lead program.
One year ago, the company expected to have data from the first phase 3 trial of its COMP360 psilocybin therapy in treatment-resistant depression by the summer of 2024. That target got pushed back to the fourth quarter early this year. At that time, top-line data from a second trial were due around the middle of 2025. Compass reset both timelines as part of its third-quarter update on Thursday.
Read the full report at Fierce Biotech
Leave a Reply
Want to join the discussion?Feel free to contribute!